Search for a doctor

Tyler S. Oesterle, M.D., M.P.H.

Publications

  1. Frye MA, Singh B, Breitinger SA, Oesterle TS. Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse: A Cautionary Tale. J Clin Psychiatry. 2024 Aug 26; 85 (3)
    View PubMed
  2. Bormann NL, Weber AN, Oesterle TS, Miskle B, Lynch AC, Arndt S. State inequities: Gaps in planned treatment for criminal legal referrals with opioid use disorder across two decades of US treatment admissions. Am J Addict. 2024 Aug 3 Epub 2024 Aug 03
    View PubMed
  3. Ho MF, Zhang C, Cohan JS, Tuncturk M, Heider RM, Coombes BJ, Biernacka J, Moon I, Skime M, Ho AM, Ngo Q, Skillon C, Croarkin PE, Oesterle TS, Karpyak VM, Li H, Weinshilboum RM. IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study. Brain Behav Immun. 2024 Aug; 120:304-314 Epub 2024 June 08
    View PubMed
  4. Fipps DC, Oesterle TS, Kolla BP. Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder. Semin Neurol. 2024 Aug; 44(4):441-451. Epub 2024 Jun 07.
    View PubMed
  5. Ho MF, Zhang C, Moon I, Zhu X, Coombes BJ, Biernacka J, Skime M, Oesterle TS, Karpyak VM, Schmidt K, Gliske K, Ngo Q, Skillon C, Seppala MD, Li H, Weinshilboum RM. Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder. Mol Psychiatry. 2024 Jun; 29 (6):1636-1646 Epub 2022 Oct 27
    View PubMed
  6. Oesterle TS, Hall-Flavin DK, Bormann NL, Loukianova LL, Fipps DC, Breitinger SA, Gilliam WP, Wu T, da Costa SC, Arndt S, Karpyak VM. Therapeutic Content of Mobile Phone Applications for Substance Use Disorders: An Umbrella Review. Mayo Clin Proc Digit Health. 2024 Jun; 2 (2):192-206 Epub 2024 Apr 11
    View PubMed
  7. Bormann NL, Oesterle TS, Arndt S, Karpyak VM, Croarkin PE. Systematic review and meta-analysis: Combining transcranial magnetic stimulation or direct current stimulation with pharmacotherapy for treatment of substance use disorders. Am J Addict. 2024 May; 33 (3):269-282 Epub 2024 Jan 25
    View PubMed
  8. Lai B, Oesterle T, Kelpin S, Morrison E, Elegbede A, Warner N. Chronic pain and opioid use disorder workshop for medical students: a biopsychosocial and multidisciplinary approach. Pain Med. 2024 Apr 3; 25 (4):306-309
    View PubMed
  9. Ho MF, Zhang C, Moon I, Tuncturk M, Coombes BJ, Biernacka J, Skime M, Oesterle TS, Karpyak VM, Li H, Weinshilboum R. Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: a multi-omics study. Transl Psychiatry. 2024 Mar 26; 14 (1):165
    View PubMed
  10. Oesterle TS, Bormann NL, Ochal DA, Arndt S, Breitinger SA. Transitioning Virtual-Only Group Therapy for Substance Use Disorder Patients to a Hybrid Model. Subst Abuse Rehabil. 2024; 15:73-78 Epub 2024 Apr 23
    View PubMed
  11. Lai B, Good J, Singh G, Deyo M, Marshall R, Oesterle T. Adolescent Substance Use Disorder in Primary Care: Challenges in Treatment Referral Beyond Access Availability. J Prim Care Community Health. 2024 Jan-Dec; 15:21501319241276817
    View PubMed
  12. Bormann NL, Stoppel CJ, Arndt S, Oesterle TS. Patient Perceived Impact of Outpatient Group Substance Use Disorder Treatment in a Hybrid Model or Virtual-Only Model Relative to In-Person Delivery. Subst Abuse Rehabil. 2024; 15:223-232 Epub 2024 Oct 25
    View PubMed
  13. Rojas Cabrera JM, Oesterle TS, Rusheen AE, Goyal A, Scheitler KM, Mandybur I, Blaha CD, Bennet KE, Heien ML, Jang DP, Lee KH, Oh Y, Shin H. Techniques for Measurement of Serotonin: Implications in Neuropsychiatric Disorders and Advances in Absolute Value Recording Methods. ACS Chem Neurosci. 2023 Dec 20; 14 (24):4264-4273 Epub 2023 Nov 29
    View PubMed
  14. Ho MF, Zhang C, Moon I, Biernacka J, Coombes B, Ngo Q, Skillon C, Skime M, Oesterle T, Croarkin PE, Karpyak VM, Li H, Weinshilboum RM. Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation. Mol Metab. 2023 Nov; 77:101798 Epub 2023 Sept 07
    View PubMed
  15. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AM, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Corrigendum to "Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder" [Drug Alcohol Depend. 243 (2023) 109753]. Drug Alcohol Depend. 2023 Sep 1; 250:110888 Epub 2023 July 11
    View PubMed
  16. Karpyak VM, Coombes BJ, Geske JR, Pazdernik VM, Schneekloth T, Kolla BP, Oesterle T, Loukianova LL, Skime MK, Ho AM, Ngo Q, Skillon C, Ho MF, Weinshilboum R, Biernacka JM. Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder. Drug Alcohol Depend. 2023 Feb 1; 243:109753 Epub 2022 Dec 24
    View PubMed
  17. Yuen J, Goyal A, Rusheen AE, Kouzani AZ, Berk M, Kim JH, Tye SJ, Abulseoud OA, Oesterle TS, Blaha CD, Bennet KE, Lee KH, Oh Y, Shin H. Oxycodone-induced dopaminergic and respiratory effects are modulated by deep brain stimulation. Front Pharmacol. 2023; 14:1199655 Epub 2023 June 20
    View PubMed
  18. Zolnour A, Eldredge CE, Faiola A, Yaghoobzadeh Y, Khani M, Foy D, Topaz M, Kharrazi H, Fung KW, Fontelo P, Davoudi A, Tabaie A, Breitinger SA, Oesterle TS, Rouhizadeh M, Zonnor Z, Moen H, Patrick TB, Zolnoori M. A risk identification model for detection of patients at risk of antidepressant discontinuation. Front Artif Intell. 2023; 6:1229609 Epub 2023 Aug 24
    View PubMed
  19. Sharma P, Holland A, Sheikh T, Novy B, Oesterle T, Platt R, Hammond CJ. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative study. PEC Innov. 2022 Dec; 1:100044 Epub 2022 Apr 28
    View PubMed
  20. Oesterle TS, Karpyak VM, Coombes BJ, Athreya AP, Breitinger SA, Correa da Costa S, Dana Gerberi DJ. Systematic review: Wearable remote monitoring to detect nonalcohol/nonnicotine-related substance use disorder symptoms. Am J Addict. 2022 Nov; 31 (6):535-545 Epub 2022 Sept 05
    View PubMed
  21. Kamath CC, Kelpin SS, Patten CA, Rummans TA, Kremers HM, Oesterle TS, Williams MD, Breitinger SA. Shaping the Screening, Behavioral Intervention, and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID-19 Era. Mayo Clin Proc. 2022 Oct; 97 (10):1774-1779 Epub 2022 July 19
    View PubMed
  22. da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M. Psychedelic drugs for psychiatric disorders. J Neurol Sci. 2022 Sep 15; 440:120332 Epub 2022 July 05
    View PubMed
  23. Ho MF, Zhang C, Moon I, Wei L, Coombes B, Biernacka J, Skime M, Choi DS, Frye M, Schmidt K, Gliske K, Braughton J, Ngo Q, Skillon C, Seppala M, Oesterle T, Karpyak V, Li H, Weinshilboum R. Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. Mol Metab. 2022 Sep; 63:101534 Epub 2022 June 22
    View PubMed
  24. Kamath C, Kelpin S, Patten CA, Rummans TA, Maradit H, Oesterle TS, Williams MD, Breitinger S. Shaping the Screening, Behavioral Intervention and Referral to Treatment (SBIRT) Model for Treatment of Alcohol Use Disorder in the COVID 19 era ? (MAYOCLINPROC-D-21-00804R1 ) Mayo Clinic Proceedings. 2022.
  25. Ho MF, Zhang C, Wei L, Zhang L, Moon I, Geske JR, Skime MK, Choi DS, Biernacka JM, Oesterle TS, Frye MA, Seppala MD, Karpyak VM, Li H, Weinshilboum RM. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. Br J Pharmacol. 2022 Jul; 179 (13):3330-3345 Epub 2022 Feb 08
    View PubMed
  26. Romanowicz M, Oesterle TS, Croarkin PE, Sutor B. Measuring patient satisfaction in an outpatient psychiatric clinic. What factors play a role? Ann Gen Psychiatry. 2022 Jan 18; 21 (1):2
    View PubMed
  27. Ho MF, Zhang C, Moon I, Coombes BJ, Biernacka J, Skime M, Choi DS, Croarkin PE, Frye MA, Ngo Q, Skillon C, Oesterle TS, Karpyak VM, Li H, Weinshilboum RM. Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder. Front Pharmacol. 2022; 13:986238 Epub 2022 Sept 01
    View PubMed
  28. Carley JA, Oesterle T. Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care? Int J Gen Med. 2021; 14:2305-2311 Epub 2021 June 03
    View PubMed
  29. Oesterle TS, Kolla B, Risma CJ, Breitinger SA, Rakocevic DB, Loukianova LL, Hall-Flavin DK, Gentry MT, Rummans TA, Chauhan M, Gold MS. Substance Use Disorders and Telehealth in the COVID-19 Pandemic Era: A New Outlook. Mayo Clin Proc. 2020 Dec; 95 (12):2709-2718 Epub 2020 Oct 21
    View PubMed
  30. Kolla BP, Oesterle T, Gold M, Southwick F, Rummans T. Infectious diseases occurring in the context of substance use disorders: A concise review. J Neurol Sci. 2020 Apr 15; 411:116719 Epub 2020 Jan 31
    View PubMed
  31. Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. J Neurol Sci. 2020 Apr 15; 411:116728 Epub 2020 Feb 11
    View PubMed
  32. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-Assisted Treatment for Opioid-Use Disorder. Mayo Clin Proc. 2019 Oct; 94 (10):2072-2086 Epub 2019 Sept 19
    View PubMed
  33. Romanowicz M, Vande Voort JL, Shekunov J, Oesterle TS, Thusius NJ, Rummans TA, Croarkin PE, Karpyak VM, Lynch BA, Schak KM. The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. Child Adolesc Psychiatry Ment Health. 2019; 13:5 Epub 2019 Jan 12
    View PubMed
  34. Oesterle TS, Hitschfeld MJ, Lineberry TW, Schneekloth TD. CRAFFT as a Substance Use Screening Instrument for Adolescent Psychiatry Admissions. J Psychiatr Pract. 2015 Jul; 21 (4):259-66
    View PubMed
  35. Cockerill RG, Biggs BK, Oesterle TS, Croarkin PE. Antidepressant use and body mass index change in overweight adolescents: a historical cohort study. Innov Clin Neurosci. 2014 Nov-Dec; 11 (11-12):14-21
    View PubMed
  36. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, Oliver WC, Abenstein JP. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014 Feb 28; 215 (2):362-5 Epub 2013 Dec 21
    View PubMed
PST-20493239